Figure 2.
Survival. PFS and OS with VEN-LEN-rituximab (A). PFS and OS according to the (B) presence or (C) absence of a TP53 mutation.
Survival. PFS and OS with VEN-LEN-rituximab (A). PFS and OS according to the (B) presence or (C) absence of a TP53 mutation.
